On December 31, 2024, researchers from the Geriatric Medical Research Center, the Institute of Respiratory Health and Multimorbidity, and the National Key Laboratory of Biotherapy at West China Hospital, including Professors Wei Xiawei, Li Weimin, Lu Guangwen, and Wang Zhenling, collaborated with researchers from the Chinese Academy of Medical Sciences and Peking Union Medical College. They published their research findings in the journal Nature Communications, titled "Trivalent recombinant protein vaccine induces cross-neutralization against XBB lineage and JN.1 subvariants: preclinical and phase 1 clinical trials," showcasing the preclinical and phase 1 clinical trial data of their developed trivalent COVID-19 vaccine, Tri-Vac. The vaccine received emergency use authorization from the Chinese Government in June 2023, marking it as the world's first recombinant protein vaccine targeting the XBB variant.

This study not only provides new theoretical support for the broad-spectrum protection of vaccines but also offers valuable practical experience in dealing with the continuous changes in virus strains. As the world's first recombinant protein vaccine targeting the XBB variant, Tri-Vac demonstrates immense potential in the global fight against COVID-19 variants.

Link to the paper: https://www.nature.com/articles/s41467-024-55087-z